Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with <i>KRAS</i> p.G13D Mutation

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with <i>KRAS</i> p.G13D Mutation

The now clinically-used anti-epidermal growth factor receptor (EGFR) monoclonal antibodies have demonstrated significant efficacy only in patients with metastatic colorectal cancer (mCRC), with wild-type Kirsten rat sarcoma viral oncogene homolog (<i>KRAS</i>). However, no effective trea...

Full description

Bibliographic Details
Main Authors: Tomokazu Ohishi, Yukinari Kato, Mika K. Kaneko, Shun-ichi Ohba, Hiroyuki Inoue, Akiko Harakawa, Manabu Kawada
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:International Journal of Molecular Sciences
Subjects:
colorectal cancer
metastasis
epidermal growth factor receptor
antibody-dependent cell cytotoxicity
complement-dependent cytotoxicity
Online Access:https://www.mdpi.com/1422-0067/21/17/6037

Internet

https://www.mdpi.com/1422-0067/21/17/6037

Similar Items